The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) awarded an Indefinite Delivery Contract (IDC) to Sandoz Inc. to supply pegfilgrastim injectables to the VA, Bureau of Prisons, and Indian Health Service. The $26,399,360.75 contract has a base period of one year and four one-year option periods, with an estimated annual requirement of 7,079 units. Sandoz Inc. is a global leader in generic pharmaceuticals and biosimilars, and has eight active IDCs with the VA to provide a variety of prescription medications through the VA and DoD pharmaceutical prime vendor programs.
The solicitation for this IDC was an unrestricted procurement, with no set-asides used. It sought to award a requirements contract for pegfilgrastim injectables, including Neulasta, Udenyca, Fulphila, and Ziextenzo, to be distributed nationwide through the VA Pharmaceutical Prime Vendor program. The contracted products aim to meet the medication needs of veterans, active duty military, federal inmates, and Native American populations served by the VA, Bureau of Prisons, and Indian Health Service healthcare networks.
Generated 1/7/25, 11:32 AM